Table 1 Baseline characteristics of patients receiving different antiviral drugsa.
Total patients | Patients after matching | |||||
|---|---|---|---|---|---|---|
Nirmatrelvir-ritonavir | Azvudine | P | Nirmatrelvir-ritonavir | Azvudine | P | |
(n = 412) | (n = 304) | (n = 219) | (n = 219) | |||
Male | 218 (52.9%) | 174 (57.2%) | 0.26 | 118 (53.9%) | 129 (58.9%) | 0.34 |
Age (year) | 72 (59–82) | 68 (59–78) | 0.043 | 72 (59–81) | 69 (59–78) | 0.38 |
Comorbidity | ||||||
Hypertension | 181 (43.9%) | 144 (47.4%) | 0.36 | 107 (48.9%) | 102 (46.6%) | 0.70 |
Diabetes mellitus | 105 (25.5%) | 88 (28.9%) | 0.31 | 61 (27.9%) | 62 (28.3%) | 1.00 |
Cerebrovascular disease | 42 (10.2%) | 28 (9.2%) | 0.70 | 23 (10.5%) | 21 (9.6%) | 0.87 |
Cardiovascular disease | 93 (22.6%) | 68 (22.4%) | 1.00 | 48 (21.9%) | 53 (24.2%) | 0.65 |
Interstitial lung disease | 16 (3.9%) | 17 (5.6%) | 0.29 | 14 (6.4%) | 9 (4.1%) | 0.39 |
Small airway disease | 29 (7.0%) | 18 (5.9%) | 0.65 | 15 (6.8%) | 16 (7.3%) | 1.00 |
Chronic liver disease | 12 (2.9%) | 5 (1.6%) | 0.33 | 2 (0.9%) | 4 (1.8%) | 0.69 |
Chronic kidney disease | 40 (9.7%) | 25 (8.2%) | 0.51 | 17 (7.8%) | 21 (9.6%) | 0.61 |
Tumour | 86 (20.9%) | 56 (18.4%) | 0.45 | 42 (19.2%) | 45 (20.5%) | 0.81 |
Immunosuppressive status | 95 (23.1%) | 53 (17.4%) | 0.076 | 47 (21.5%) | 42 (19.2%) | 0.63 |
Baseline disease severity | < 0.001 | 0.86 | ||||
Not admitted to hospital and able to resume normal activities | 90 (21.8%) | 37 (12.2%) | 30 (13.7%) | 33 (15.1%) | ||
Not admitted to hospital but unable to resume normal activities | 105 (25.5%) | 147 (48.4%) | 93 (42.5%) | 81 (37.0%) | ||
Admitted to hospital but not requiring supplemental oxygen | 47 (11.4%) | 16 (5.3%) | 14 (6.4%) | 15 (6.8%) | ||
Admitted to hospital and requiring supplemental oxygen | 145 (35.2%) | 92 (30.3%) | 74 (33.8%) | 80 (36.5%) | ||
Admitted to hospital and requiring HFNC, NIV, or both# | 11 (2.7%) | 11 (3.6%) | 8 (3.7%) | 9 (4.1%) | ||
Admitted to hospital and requiring IMV, ECMO, or both# | 14 (3.4%) | 1 (0.3%) | 0 (0.0%) | 1 (0.5%) | ||
Death | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
Baseline respiratory support | 0.060 | 0.22 | ||||
No respiratory support | 242 (58.7%) | 200 (65.8%) | 137 (62.6%) | 129 (58.9%) | ||
Conventional respiratory support | 121 (29.4%) | 82 (27.0%) | 55 (25.1%) | 70 (32.0%) | ||
Advanced respiratory support | 49 (11.9%) | 22 (7.2%) | 27 (12.3%) | 20 (9.1%) | ||
Duration from symptom onset to drug initiation (d) | 4 (2–10) | 9 (5–13) | < 0.001 | 5 (3–11) | 9 (5–12) | < 0.001 |
Corticosteroid | 199 (48.3%) | 177 (58.2%) | 0.010 | 118 (53.9%) | 122 (55.7%) | 0.77 |
Tocilizumab | 58 (14.1%) | 37 (12.2%) | 0.50 | 33 (15.1%) | 30 (13.7%) | 0.79 |
Baricitinib | 30 (7.3%) | 10 (3.3%) | 0.022 | 8 (3.7%) | 9 (4.1%) | 1.00 |
